Which of the following is/are FDA-approved indication(s) for valacyclovir hydrochloride? Select all that apply

Valacyclovir is an L-valyl ester prodrug of the purine nucleoside analogue acyclovir, utilized for the inhibition of viral DNA polymerase. It exhibits high oral bioavailability and is converted in the liver to acyclovir, which competes with deoxyguanosine triphosphate. It is primarily indicated for DNA viruses such as Varicella-Zoster and Herpes Simplex. Side effects include headache and nausea, while severe cases may involve thrombotic thrombocytopenic purpura. Rationale: A. Herpes zoster, commonly known as shingles, is a primary FDA-approved indication for valacyclovir. The drug accelerates the resolution of lesions and reduces the duration of postherpetic neuralgia by inhibiting viral replication. Treatment is most effective when initiated within 72 hours of rash onset to limit neuralgic damage. Its high plasma concentration facilitates effective suppression of the Varicella-Zoster virus. B. Tinea pedis is a fungal infection of the feet caused by dermatophytes, such as Trichophyton rubrum. Valacyclovir is strictly an antiviral agent and possesses no pharmacological activity against fungal organisms. Fungal cell walls contain ergosterol, whereas valacyclovir targets viral DNA synthesis. Consequently, this medication is completely ineffective for treating athlete's foot or any other mycotic infection. C. Genital herpes is a major FDA-approved indication for valacyclovir, used for both acute outbreaks and long-term suppressive therapy. By decreasing viral shedding, the medication reduces the risk of transmission to seronegative partners. It is effective against both Herpes Simplex Virus type 1 and type 2. Suppression protocols typically involve daily dosing to maintain adequate virological control in the host. D. Infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) require bactericidal or bacteriostatic antibiotics like vancomycin or daptomycin. Valacyclovir has no effect on bacterial cell wall synthesis or protein synthesis. Bacteria are prokaryotic organisms, while valacyclovir is specifically designed to interfere with viral replication machinery. Using an antiviral for a bacterial pathogen like MRSA would result in treatment failure.